Bienvenue sur le forum TechNet

In partnership with Arecor and the University of Colorado Denver School of Pharmacy, PATH published findings in this month’s issue of Human Vaccines (volume 5, issue 8) that describe a new hepatitis B vaccine formulation exhibiting nine week stability at 55°C and at least six month stability at both...

Long-term Cold Storage Containers and Carriers for Heat/Freeze-sensitive Vaccines: Target Performance Criteria by Steve McCarney, PATH Project Optimize, a collaboration between the World Health Organization (WHO) and PATH, seeks to develop and galvanize support around a vision for the future of i...

Temperature Monitoring Study To Commence in Vietnam and Uganda by Joanie Robertson, Huong Vu and James Cheyne, PATH While some vaccines will lose their potency if they are stored at temperatures above or below the standard 2° to 8°C, many vaccines are quite heat stable and can tolerate temperatures...

The Advanced Immunization Management (AIM) e-Learning website recently launched a new module to help decision-making on rotavirus vaccine introduction. The module provides comprehensive information from basic disease characteristics through immunization session planning; this interactive online to...

POST 01383E: HepB VACCINATION SCHEDULE 4 FEBRUARY 2009 ****************************************** We have a question from Dr Sajad ([email protected]), the National EPI Training officer in the Ministry of Public Health Afghanistan. He asks: If a person receives the Hep B monovalent vaccine,...

POST 01372E: E-LEARNING MODULES—IMMUNIZATION FINANCING/ INTRODUCING NEW VACCINES 11 JANUARY 2009 ****************************************** Padmini, A useful introduction to the subject is AIM e-Learning: Immunization Financing Module at www.aim.path.org/en/finance/index.html Tasnim Partapuri...

POST 01364E: NEEDLESTICK PREVENTION DEVICES19 DECEMBER 2008 ****************************************** According to the World Health Report 2002, ‘there are 35 million health-care workers, of which 2 million experience percutaneous exposure to infectious diseases each year. The report also states...

POST 01344E: POLIO ERADICATION VS CONTROL—ADDITIONAL ASPECTS TO CONSIDER FOLLOW-UP ON POSTS 01339E, 01341E, 013342E & 01343E 31 OCTOBER 2008 ****************************************** CONTROL MORE EXPENSIVE IN THE LONG RUN Hans, I agree with you. You may recall that I was seconded from ...

POST 01292E: NEEDLE-FREE/COLD CHAIN-FREE VACCINE DELIVERY 20 JULY 2008 ******************************************* A peep into the future with regard to needle-free vaccine delivery reveals that innumerable innovative technologies are being researched to deliver vaccines. These range from aerosol...

POST 01268E: WORLD HEPATITIS DAY 19 MAY 2008 ******************************************* Chronic viral hepatitis can no longer be ignored. The figures are rather staggering. Take a look at the statistics: Ø 500 million people worldwide currently infected with hepatitis B or C Ø This is over 10...

POST 01158E : VACCINE OUT-OF-THE-COLD-CHAIN 17 September 2007 The following article describes the use of an out-of-the-cold-chain immunization strategy to improve the timeliness of the HB birth dose in rural China. It showed a large improvement in the ability to reach newborns within 24 hours of...

POST 01067E : MEASLES GOAL ACHIEVED Follow-up on Post 01049E (http://listes.ulaval.ca/cgi-bin/wa?A2=i ... .org&P=175) 20 March 2007 NOTE : As you notice, we now insert the direct link to the previous posting on the topic to facilitate access for consultation. Robert Steinglass (mailto...

Post 01048E : HEPATITIS B VACCINATION IMPACT Follow-up on Post 01039E 2 February 2007 Following the last posting on this topic, Bob Chen (mailto:[email protected]) from CDC, USA, has sent this article : "Nationwide Hepatitis B Vaccination Program in Taiwan: Effectiveness in the 20 Years Aft...

POST 01039E : HEPATITIS B VACCINATION IMPACT 14 January 2007 As they are rather light, we attach to this posting two resumes of articles showing that HepB vaccination produces, after a period of years, sustained declines in hepatitis B incidence in vaccinated birth cohorts. The first "...

POST 01007E : 8 November 2006 NOTE : The link to Julie Milstien's second presentation provided in Post 01002E is functional at last. My apologies for nor having been able to identify the problem earlier. (http://www.technet21.org/Mexico/Milstie ... ccines.ppt) Carib Nelson (mailto:cnel...

POST 01007E : 8 November 2006 NOTE : The link to Julie Milstien's second presentation provided in Post 01002E is functional at last. My apologies for nor having been able to identify the problem earlier. (http://www.technet21.org/Mexico/Milstie ... ccines.ppt) Carib Nelson (mailto:cnel...

POST 00989E : VVM USE AND FREEZE INDICATORS Follow-up on Posts 00960E, 00962E, 00964E, 00970E, 00973E, 00975E and 00978E 11 October 2006 This posting contains two short contributions. The first, originally in French, is from Abdoulaye Djigo (mailto:[email protected]) from Senegal if...

POST 00980E : COLD CHAIN CAPACITY ASSESSMENT Follow-up on Posts 00965E, 00971E and 00974E 27 September 2006 This posting contains four contributions. from Anil Varshney ([log in to unmask]mailto:anil[log in to unmask]) from India. from Andrew Garnett ([log in to unmask]mailto:[log in to unm...

POST 00964E : VVM USE / INDONESIA Follow-up on Posts 00960E and 00962E 18 August 2006 Pradeep Haldar (mailto:[email protected]) from India, makes some clarification about Vijaya Kiran's contribution. Then Debra Kristensen (mailto:[email protected]), Anton Widjaya (mailto:widjaya@...

POST 00918E : VACCINATION DECISION TOOL Follow-up on Post 00913E 30 April 2006 The following contribution comes from Kaushik Banerjee (mailto:[email protected]) from WHO. Thank you for sharing this useful tool. I had earlier shared some of the comments below with Robert Steinglass. The ...